Sunitinib and pazopanib are both standard first-line therapies for clear-cell metastatic renal-cell carcinoma (mRCC). Everolimus is a well-established second-line treatment.
To estimate the efficacy and safety of second-line everolimus following pazopanib or sunitinib.